Novartis, Bayer consider appeal as court says Avastin can be used in AMD

06:19 EDT 24 Sep 2018 | pharmaphorum

England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs from Novartis and Bayer. While NHS organisations welcomed ...

Original Article: Novartis, Bayer consider appeal as court says Avastin can be used in AMD

More From BioPortfolio on "Novartis, Bayer consider appeal as court says Avastin can be used in AMD"